Kilitch Drugs (India) Limited
Dipak Kanayalal Shah decreased his stake in Kilitch Drugs (India) from 3.64% to 3.20% by selling 1,52,500 shares. The sale was valued at ₹2.79 crore, with shares transacting at ₹183.12 apiece.
A pharmaceutical manufacturer engaged in the production and distribution of generic drugs and pharmaceutical formulations across India. Incorporated in 1978, Kilitch Drugs operates across multiple therapeutic segments including cardiovascular, gastrointestinal, respiratory, and anti-infective treatments. The company serves hospitals, clinics, and retail pharmacy channels through its established distribution infrastructure, catering to both domestic markets and institutional healthcare providers.
A quiet accumulator of India's most overlooked microcap businesses. Built a ~₹152 Cr portfolio across 35 companies spanning specialty chemicals, pharma, packaging, and industrial components, mostly names that don't appear in any analyst's coverage universe. Portfolio DNA overlaps significantly with Sharad Kanayalal Shah, pointing to a disciplined family approach to finding businesses the market has completely ignored.